Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab tirumotecan (SKB264) + QL1706 in recurrent or metastatic cervical cancer (phase II, single-arm)
ChiCTR2500111257Phase 2Not yet recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Nov 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of sacituzumab tirumotecan and QL1706 in Cervical Cancer (CC), cervical squamous cell carcinoma (CSCC), cervical adenocarcinoma and 1 more (2 cohorts), sponsored by Fujian Medical University Cancer Hospital. Primary endpoint: Objective Response Rate (ORR). Planned start Nov 2025; status: not yet recruiting.
02
Drugs
sacituzumab tirumotecanQL1706
03
Conditions
Cervical Cancer (CC)cervical squamous cell carcinoma (CSCC)cervical adenocarcinomaAdenosquamous Cervical Cancer (ASC)
Beyond the preview
Go deeper on ChiCTR2500111257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500111257.